Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that biologic therapies, particularly anti-TNF-alpha agents, have been linked to increased cases of alopecia areata in patients treated for autoimmune disorders.

This review discusses the increased autoimmune events associated with the use of denosumab, a biologic agent for managing postmenopausal osteoporosis and skeletal complications from malignancy, but reports no new data.

In this case report, a 67-year-old woman experienced patchy hair loss, likely related to denosumab treatment for osteoporosis, as other potential causes were ruled out; stopping denosumab led to hair regrowth following intralesional triamcinolone treatment, suggesting a potential denosumab-induced alopecia areata.

In this case report, the researchers observed scalp alopecia due to metastasis of breast cancer in a woman in her sixties, highlighting that scalp metastases can result in patchy hair loss and, although often accompanied by poor prognosis, can sometimes show comparatively better outcomes.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.